Healthy Returns: Sales of Humira are plunging, but AbbVie has two promising successors
Publishing timestamp: 2024-05-01 09:31:44
Summary
AbbVie's sales of Humira are plummeting due to competition from biosimilars, but the company's newer drugs Skyrizi and Rinvoq are proving to be successful successors. Despite the competition, AbbVie reported strong revenue and profit in the first quarter. Meanwhile, UnitedHealth Group's CEO will testify on Capitol Hill about a cyberattack on its subsidiary, Change Healthcare.
Sentiment: MIXED
Tickers: TEVA-IL, ABBV, UNH, TEVA, ALVO, CVS,
Keywords: cvs health corp, abbvie inc, teva pharmaceutical industries ltd, rick gonzalez, united states, health care industry, biotech and pharmaceuticals, alvotech sa, unitedhealth group inc, business news,